Find an Article

Filter articles

Applied Filters

Showing 201 to 210 of 277 results

Brazil focus: Protecting plant varieties—without IP law

Brazil16-06-2015Renata Campello Afonso

There is increasing demand for plant variety protection in Brazil. Renata Campello Afonso of Luiz Leonardos & Advogados reports.

Plant patentability: The scope of exclusion provisions

EU16-06-2015Albrecht von Menges

The Enlarged Board of Appeal of the European Patent Office has issued the second decisions in the so-called Broccoli and Tomato cases. Albrecht von Menges of Uexküll & Stolberg examines the decisions and their implications.

Stemming the tide of rejections

Mexico16-06-2015Jasmin Maqueda

Mexican patent examiners usually reject patents directed to human embryonic stem cells, but applications filed after 2008 may have a greater chance of being approved, as Jasmin Maqueda of Becerril, Coca & Becerril describes.

Ogres and trolls

US16-06-2015Steve Coyle, Leslie-Anne Maxwell, Chad Dever

The inter partes review system was set up as a cheaper way of invalidating patents than litigation. Given the high success rate, and the large number of ‘patent trolls’ involved, is it likely that troll activity will be dampened? Steve Coyle, Leslie-Anne Maxwell and Chad Dever of Cantor Colburn investigate.

TPP: Coming into line


As far we know, the IP chapter in the proposed Trans-Pacific Partnership agreement contains provisions on modernising plant breeders’ rights, but not all the participating countries are currently on the same page, as LSIPR reports.

Tax matters: A level playing field

EU, UK16-06-2015

How will the OECD’s Modified Nexus Approach to innovator-friendly tax regimes such as the UK’s patent box affect the life sciences industry? LSIPR investigates.

Preview: 2015 BIO International Convention


LSIPR picks five sessions IP professionals won’t want to miss at this year’s BIO International Convention in Philadelphia, from June 15 to 18.

IP in Australia: major changes in store


February’s amendments to the Australian IP Act seek to increase the effectiveness and efficiency of the country’s IP system. LSIPR takes a look at the major changes and considers who will benefit most in the life sciences sector.

A trump card for challengers

EU30-04-2015Hazel Ford and Leythem Wall

For companies that are considering conducting patent litigation around the world, the EPO is a very useful forum for testing their strategy or opposition tactics at a relatively low cost. Hazel Ford and Leythem Wall of Finnegan, Henderson, Farabow, Garrett & Dunner describe the numerous advantages of the procedures available.

Case review: Biogen v Medeva, 20 years on


Some of the parties involved in the landmark patent case Biogen v Medeva met in London in February to discuss the dispute in front of an invited audience. Here is an overview of their memories and the lessons they learned.

Showing 201 to 210 of 277 results